NCT05692570View on ClinicalTrials.gov

A Study of PBI-200 With Ritonavir or Cobicistat in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

September 9, 2022

Primary Completion Date

November 12, 2022

Study Completion Date

November 12, 2022

Conditions
Drug-drug Interaction
Interventions
DRUG

PBI-200 Tablet

PBI-200 is a TRK inhibitor

DRUG

Ritonavir Oral Tablet

Ritonavir is a potent CYP3A inhibitor

DRUG

Cobicistat Oral Tablet

Cobicistat is a potent CYP3A inhibitor

Trial Locations (1)

85283

Celerion, Inc., Tempe

Sponsors
All Listed Sponsors
lead

Pyramid Biosciences

INDUSTRY